Nabi Biopharmaceuticals (NABI) - Financial and Strategic SWOT Analysis Review

GlobalData, September 2011, Pages: 42

Nabi Biopharmaceuticals (NABI) - Financial and Strategic SWOT Analysis Review

Summary

Nabi Biopharmaceuticals (Nabi) is a a bio-pharmaceutical company engaged in the development and marketing of vaccines for the treatment of serious medical conditions in the field of nicotine addiction and infectious disease. The company is focused on the development of first and second generation products that address unmet medical needs. The research and development pipeline products of the company includes, several novel vaccines in various stages of development for the treatment of nicotine addition and Gram-positive bacterial infections. Currently, the company is engaged in the development of NicVAX (Nicotine Conjugate Vaccine), an innovative and proprietary investigational vaccine to treat nicotine addiction and prevent smoking relapse. Nabi is headquartered in Rockville, Maryland, the US.

Nabi Biopharmaceuticals Key Recent Developments

Aug 03, 2011 Nabi Biopharmaceuticals Reports Total Revenue Of $3.7m For Q2 2011
May 05, 2011 Nabi Biopharmaceuticals Reports Net Income Of $2m For Q1 2011
Mar 08, 2011 Nabi Biopharmaceuticals Reports Net Loss Of $6.3m For Q4 2010
Nov 03, 2010 Nabi Reports Net Income Of $5.1 Million For Q3 2010
Aug 24, 2010 Nabi Biopharmaceuticals Receives New Patent From US Patent And Trademark Office

This comprehensive SWOT profile of Nabi Biopharmaceuticals provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

List of Tables
List of Figures
Section 1 - About the Company
Nabi Biopharmaceuticals - Key Facts
Nabi Biopharmaceuticals - Key Employees
Nabi Biopharmaceuticals - Key Employee Biographies
Nabi Biopharmaceuticals - Major Products and Services
Nabi Biopharmaceuticals - Pharmaceutical Pipeline Products Data
Nabi Biopharmaceuticals, Pipeline Products by Therapy Area
Nabi Biopharmaceuticals, Pipeline Products by Development Phase
Nabi Biopharmaceuticals - History
Nabi Biopharmaceuticals - Company Statement
Nabi Biopharmaceuticals - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Nabi Biopharmaceuticals - Business Description
Nabi Biopharmaceuticals - Corporate Strategy
Nabi Biopharmaceuticals - SWOT Analysis
SWOT Analysis - Overview
Nabi Biopharmaceuticals - Strengths
Strength - Fast Track and SPA Designations
Strength - Strategic Collaboration
Strength - Strong Product portfolio
Weakness - Lack of Product Based Revenues
Weakness - Dependency On Third-Party Manufacturing Facility
Opportunity - RENS Technology Platform
Opportunity - Strategic Transactions With GSK
Opportunity - Rising Healthcare Expenditure in the US
Opportunity - Nicotine Treatment Products
Threat - Tightening of the FDA’s Regulatory Oversight
Threat - Uncertain R&D Outcomes
Threat - Competitive Pressure
Nabi Biopharmaceuticals - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Nabi Biopharmaceuticals, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
Nabi Biopharmaceuticals, Pharmaceuticals & Healthcare, Deals By Type, 2005 to YTD 2011
Nabi Biopharmaceuticals, Recent Deals Summary
Section 5 – Company’s Recent Developments
Aug 03, 2011: Nabi Biopharmaceuticals Reports Total Revenue Of $3.7m For Q2 2011
May 05, 2011: Nabi Biopharmaceuticals Reports Net Income Of $2m For Q1 2011
Mar 08, 2011: Nabi Biopharmaceuticals Reports Net Loss Of $6.3m For Q4 2010
Nov 03, 2010: Nabi Reports Net Income Of $5.1 Million For Q3 2010
Aug 24, 2010: Nabi Biopharmaceuticals Receives New Patent From US Patent And Trademark Office
Aug 05, 2010: Nabi Biopharmaceuticals Reports Net Loss Of $3.4 Million For Q2 2010
Jul 14, 2010: Nabi Biopharmaceuticals Completes Enrollment Of First Nicvax Phase Iii Clinical Trial
May 06, 2010: Nabi Reports Net Income Of $5.5 Million For Q1 2010
Apr 05, 2010: Nabi Biopharmaceuticals Prevails In Opposition To Drug Abuse Therapy Patent
Mar 17, 2010: Nabi Biopharmaceuticals Initiates Second Phase Iii Study For Nicvax As An Aid To Smoking Cessation And Long-Term Abstinence
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Nabi Biopharmaceuticals, Key Facts
Nabi Biopharmaceuticals, Key Employees
Nabi Biopharmaceuticals, Key Employee Biographies
Nabi Biopharmaceuticals, Major Products and Services
Nabi Biopharmaceuticals, Number of Pipeline Products by Therapy Area
Nabi Biopharmaceuticals, Number of Pipeline Products by Development Stage
Nabi Biopharmaceuticals, Pipeline Products By Therapy Area and Development Phase
Nabi Biopharmaceuticals, History
Nabi Biopharmaceuticals, Other Locations
Nabi Biopharmaceuticals, Key Competitors
Nabi Biopharmaceuticals, Ratios based on current share price
Nabi Biopharmaceuticals, Annual Ratios
Nabi Biopharmaceuticals, Interim Ratios
Nabi Biopharmaceuticals, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
Nabi Biopharmaceuticals, Pharmaceuticals & Healthcare, Deals By Type, 2005 to YTD 2011
Nabi Biopharmaceuticals, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Nabi Biopharmaceuticals, Pipeline Products by Therapy Area
Nabi Biopharmaceuticals, Pipeline Products by Development Phase
Nabi Biopharmaceuticals, Performance Chart (2006 - 2010)
Nabi Biopharmaceuticals, Ratio Charts
Nabi Biopharmaceuticals, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
Nabi Biopharmaceuticals, Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011

Independent Pharmaceutica AB
Celtic Pharmaceutical Holdings L.P.
GlaxoSmithKline plc
Cytos Biotechnology AG
Pfizer Inc.

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• eBay - Strong Execution
• Scientific Games Corporation - Company Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Amazon - Point of Realization in 2013?
• SunGard - Profile - US
• Ixia - Company Analysis
• Insight into Samsung Electronics' Notebook PC Business Model
• US - Accenture - Company Profile